Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 16/20 | 0.47 |
| ▸ | CNR2 | P34972 | 8/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4838446 | 0.94 | CNR1 (0.47) | CNR1CNR2 | |
| SCHEMBL1315433 | 0.92 | CNR1 (0.54) | CNR1CNR2HSD17B10 | |
| SCHEMBL4841160 | 0.92 | CNR1 (0.48) | CNR1CNR2KMT2A | |
| SCHEMBL4837396 | 0.91 | CNR1 (0.47) | CNR1CNR2HSD17B10DGAT2 | |
| SCHEMBL4842356 | 0.91 | CNR1 (0.47) | CNR1CNR2DGAT2 | |
| SCHEMBL4845084 | 0.90 | CNR1 (0.46) | CNR1CNR2MEN1KMT2A | |
| SCHEMBL4842714 | 0.90 | CNR1 (0.49) | CNR1CNR2MEN1KMT2A | |
| SCHEMBL4837562 | 0.89 | CNR1 (0.45) | CNR1CNR2 | |
| SCHEMBL4838215 | 0.84 | CNR1 (0.63) | CNR1CNR2 | |
| SCHEMBL4833674 | 0.83 | CNR1 (0.55) | CNR1CNR2DGAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329658-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER INC (US) | 2008-02-12 | — | — | US | claimed |
| EP-1592691-A1 | PYRAZOLO[1,5-A][1,3,5]TRIAZINE DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS | Pfizer Products Inc. (US) | 2005-11-09 | — | — | EP | claimed |
| WO-2004069837-A1 | PYRAZOLO`1,5-A!`1,3,5!TRIAZINE DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS | PFIZER PRODUCTS INC. (US) | 2004-08-19 | — | — | WO | claimed |
| US-20040157839-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-08-12 | — | — | US | claimed |
| US-7329658-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER INC (US) | 2008-02-12 | — | — | US | disclosed |
| WO-2006111424-A1 | METHODS FOR IDENTIFYING MODULATORS OF CB1 AND CB2 CANNABINOID RECEPTORS AND THEIR USE IN WOUND HEALING | LIFE & BRAIN GMBH (DE) | 2006-10-26 | — | — | WO | disclosed |
| EP-1592691-A1 | PYRAZOLO[1,5-A][1,3,5]TRIAZINE DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS | Pfizer Products Inc. (US) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004069837-A1 | PYRAZOLO`1,5-A!`1,3,5!TRIAZINE DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS | PFIZER PRODUCTS INC. (US) | 2004-08-19 | — | — | WO | disclosed |
| US-20040157839-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157839-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | CNR1 1/4885CNR2 2/4885MEN1 4394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.